利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.015 秒)

    Use of PTA peptides for stratification of individuals having cancer
    2.
    发明公开
    Use of PTA peptides for stratification of individuals having cancer 审中-公开
    Verwendung von PTA PeptidenfürSchichtung der Personen，die Krebs haben

    公开(公告)号：EP1742059A1

    公开(公告)日：2007-01-10

    申请号：EP04029171.8

    申请日：2004-12-09

    申请人： DIGILAB BioVisioN GmbH

    发明人： Tammen, Herald, Dr. ,  Pich, Andreas, Dr. ,  Traub, Frank, Dr. ,  Hess, Rüdiger, Dr. ,  Lamping, Norbert, Dr. ,  Schorn, Karl, Dr. ,  Kreipe, Hans, Prof. Dr.

    IPC分类号： G01N33/574 ,  C07K14/575 ,  C07K16/26 ,  C12N15/00 ,  C12N5/00 ,  A61P35/00

    CPC分类号： G01N33/57449 ,  G01N33/57415 ,  G01N33/57434 ,  G01N2333/5759 ,  G01N2800/52

    摘要： Several types of cancer cells are treated with specialized therapies, as they have specific properties such as steroid-dependant, especially estradiol-dependant growth. Breast cancer and colon cancer cells often depend to some extend on estradiol-mediated growth signals. Therefore, especially breast cancer patients are routinely tested for the presence of estradiol receptors by immune histology. If the estradiol receptor is present usually an anti-estradiol therapy is used to eradicate the tumour and to prevent rezidives. However to a certain extend this therapy does not work and it would be an advantage to know this as early as possible, thereby not to loose any time with wrong therapy concepts. Therefore a better predictive marker to diagnose steroid-dependant cancer cells is necessary, which is provided by this invention. Prothymosin alpha (PTA) can be measured in tissue samples and plasma of breast cancer and colon cancer patients and indicates, whether the estradiol pathway is functional and consequently whether anti-estradiol therapy may be successful. PTA can be a surrogate for estradiol receptor detection by immune histology, can be a marker to monitor resistance of cancer cells towards anti-estradiol therapy and has the advantage to be determined from easily accessible patient samples such as serum or plasma. Claimed are PTA peptides and nucleic acids, binding agents therefore, test kits and diagnostic and therapeutic methods and compositions.

    摘要翻译： 用专门的疗法治疗几种类型的癌细胞，因为它们具有特定的性质，例如类固醇依赖性，特别是雌二醇依赖性生长。 乳腺癌和结肠癌细胞通常依赖于雌二醇介导的生长信号。 因此，特别是乳腺癌患者通过免疫组织学常规测试雌二醇受体的存在。 如果雌二醇受体通常存在，则使用抗雌二醇治疗来消除肿瘤并防止溃疡。 然而，在某种程度上，这种治疗方法不起作用，并且尽可能早地知道这一点是有利的，因此不会因为错误的治疗概念而放松任何时间。 因此，本发明提供了一种用于诊断类固醇依赖性癌细胞的更好的预测标记。 可以在组织样本和乳腺癌和结肠癌患者的血浆中测量孕激素α（PTA），并指示雌二醇途径是否功能，从而抗雌二醇治疗是否可以成功。 PTA可以作为通过免疫组织学检测雌二醇受体的替代物，可以作为监测癌细胞抵抗抗雌二醇治疗的抗性的标志物，并具有从容易获得的患者样品如血清或血浆中确定的优点。 据称是PTA肽和核酸，因此结合剂，测试试剂盒以及诊断和治疗方法和组合物。

    Thymosin B15 as a marker in diagnosis and prognosis of cancer
    4.
    发明公开
    Thymosin B15 as a marker in diagnosis and prognosis of cancer 失效
    胸腺素B15 als Marker in der Diagnosis und Prognows von Krebs

    公开(公告)号：EP1270745A3

    公开(公告)日：2004-06-09

    申请号：EP02020049.9

    申请日：1997-06-13

    申请人： CHILDREN'S MEDICAL CENTER CORPORATION

    发明人： Zetter, Bruce R. ,  Bao, Lere

    IPC分类号： G01N33/574 ,  C12Q1/68

    CPC分类号： G01N33/57484 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57488 ,  G01N2333/5759 ,  Y10S435/81

    摘要： The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin β family. This novel protein, herein referred to as thymosin β15, has the ability to bind and sequester G-actin, like other members of the thymosin β family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin β15 gene (SEQ ID NO: 1) and having deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that the enhanced transcripts (mRNA) and expression of the thymosin β15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.

    摘要翻译： 本发明人已经发现人类具有编码胸腺素β家族的新蛋白质的基因。 这种称为胸腺素β15的新型蛋白质具有如胸腺素β家族其他成员结合和螯合G-肌动蛋白的能力，但不同于已知的其他成员也直接调节前列腺癌细胞的细胞运动性。 分离人胸腺素β15基因（SEQ ID NO：1）的cDNA并推断出氨基酸序列（SEQ ID NO：2）。 本发明人已经表明，非睾丸细胞中增强的转录本（mRNA）和胸腺素β15基因的表达与许多癌症如前列腺，肺，黑素瘤和乳腺癌中的疾病状态具有高度相关性，特别是 转移性癌症。 因此，在非睾丸组织中发现增强的转录物或基因产物水平不仅可以用于诊断方式，而且可用于特定癌症的预后。

    Thymosin B15 as a marker in diagnosis and prognosis of cancer
    8.
    发明公开
    Thymosin B15 as a marker in diagnosis and prognosis of cancer 失效
    Verfahren zur诊断von Prostatakrebs

    公开(公告)号：EP1270745A2

    公开(公告)日：2003-01-02

    申请号：EP02020049.9

    申请日：1997-06-13

    申请人： CHILDREN'S MEDICAL CENTER CORPORATION

    发明人： Zetter, Bruce R. ,  Bao, Lere

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： G01N33/57484 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57488 ,  G01N2333/5759 ,  Y10S435/81

    摘要： The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin β family. This novel protein, herein referred to as thymosin β15, has the ability to bind and sequester G-actin, like other members of the thymosin β family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin β15 gene (SEQ ID NO: 1) and having deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that the enhanced transcripts (mRNA) and expression of the thymosin β15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.

    摘要翻译： 本发明人已经发现人类具有编码胸腺素β家族的新蛋白质的基因。 这种称为胸腺素β15的新型蛋白质具有如胸腺素β家族其他成员结合和螯合G-肌动蛋白的能力，但不同于已知的其他成员也直接调节前列腺癌细胞的细胞运动性。 分离人胸腺素β15基因（SEQ ID NO：1）的cDNA并推断出氨基酸序列（SEQ ID NO：2）。 本发明人已经表明，非睾丸细胞中增强的转录本（mRNA）和胸腺素β15基因的表达与许多癌症如前列腺，肺，黑素瘤和乳腺癌中的疾病状态具有高度相关性，特别是 转移性癌症。 因此，在非睾丸组织中发现增强的转录物或基因产物水平不仅可以用于诊断方式，而且可用于特定癌症的预后。